Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse
about
The Potential for Misuse and Abuse of Medications in ADHD: A ReviewPharmacological interventions for adolescents and adults with ADHD: stimulant and nonstimulant medications and misuse of prescription stimulantsAmphetamine, past and present--a pharmacological and clinical perspectiveFuture pharmacological treatments for substance use disordersThe intersection of attention-deficit/hyperactivity disorder and substance abuseLisdexamfetamine Dimesylate: Prodrug Delivery, Amphetamine Exposure and Duration of EfficacyTreating comorbid anxiety and depression: Psychosocial and pharmacological approachesLong-acting stimulants for treatment of attention-deficit/hyperactivity disorder: a focus on extended-release formulations and the prodrug lisdexamfetamine dimesylate to address continuing clinical challengesPharmacotherapy for stimulant-related disordersUpdate on the management of attention-deficit/hyperactivity disorder in children and adults: patient considerations and the role of lisdexamfetamine.A systematic review of the safety of lisdexamfetamine dimesylate.Lisdexamfetamine dimesylate (vyvanse), a prodrug stimulant for attention-deficit/hyperactivity disorderLisdexamfetamine dimesylate: a new therapeutic option for attention-deficit hyperactivity disorder.An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adultsFocus on Lisdexamfetamine: A Review of its use in Child and Adolescent Psychiatry.Pharmacotherapeutics directed at deficiencies associated with cocaine dependence: focus on dopamine, norepinephrine and glutamate.Attention-deficit/hyperactivity disorder in postsecondary studentsPharmacotherapeutics for substance-use disorders: a focus on dopaminergic medications.Preclinical Assessment of Lisdexamfetamine as an Agonist Medication Candidate for Cocaine Addiction: Effects in Rhesus Monkeys Trained to Discriminate Cocaine or to Self-Administer Cocaine in a Cocaine Versus Food Choice Procedure.Agonist replacement therapy for cocaine dependence: a translational review.Treating attention-deficit/hyperactivity disorder in adults: focus on once-daily medications.Pilot study of the effects of lisdexamfetamine on cocaine use: A randomized, double-blind, placebo-controlled trialStudy protocol: a dose-escalating, phase-2 study of oral lisdexamfetamine in adults with methamphetamine dependenceSubstance-use disorders in adolescents and adults with ADHD: focus on treatment.Risk based in vitro performance assessment of extended release abuse deterrent formulationsDissociable effects of the prodrug phendimetrazine and its metabolite phenmetrazine at dopamine transporters.Lisdexamfetamine in the treatment of adolescents and children with attention-deficit/hyperactivity disorder.Lisdexamfetamine dimesylate: a new option in stimulant treatment for ADHD.The rationality for using prodrug approach in drug discovery programs for new xenobiotics: opportunities and challenges.The use of lisdexamfetamine dimesylate for the treatment of ADHD.The pharmacology and clinical outcomes of amphetamines to treat ADHD: does composition matter?Current approaches in tamper-resistant and abuse-deterrent formulations.Pharmacological and clinical dilemmas of prescribing in co-morbid adult attention-deficit/hyperactivity disorder and addiction.An update on lisdexamfetamine dimesylate for the treatment of attention deficit hyperactivity disorder.Evidence-based guidelines for the pharmacological management of attention deficit hyperactivity disorder: update on recommendations from the British Association for Psychopharmacology.The use of lisdexamfetamine dimesylate for the treatment of ADHD and other psychiatric disorders.Abuse-deterrent formulations: part 2: commercial products and proprietary technologies.Lisdexamfetamine for binge eating disorder in adults: a systematic review of the efficacy and safety profile for this newly approved indication - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?An overview of prodrug technology and its application for developing abuse-deterrent opioids.The safety of extended-release drug formulations for the treatment of ADHD.
P2860
Q22241206-CDF901BB-9FEE-4398-A359-CE39620EC74BQ22241445-F00AE676-F015-44D6-A347-A687B9292B79Q22241826-E2B018A6-824A-4C1A-83E9-CA04F07D3AA2Q22242633-CFA812A9-4525-4B71-A533-CD8AD2D9685BQ22242685-E0559F9F-F896-4C23-B3BE-61C0E8CB0506Q26750486-671E8C36-A5A3-4EC9-B469-3FE612C1AEFAQ26770334-576AE169-1222-4234-A438-B52433515CDAQ26822392-FFF41696-F8D6-41F5-9F50-A6A72C304BA2Q26829186-A72B99EF-92F5-48E0-905B-C6EAD4769445Q33571016-0F458894-A231-4BD8-80D2-57FFDDE1C50EQ33755396-0469139A-15D5-42B5-92FF-C52B015803B8Q33865315-5B0EADEC-98FD-4A7B-B2D8-B609120E6A5BQ34032634-C834413E-4809-4DE7-846A-196D713C360FQ34220004-54B0E8DE-2C37-4D17-9A6C-9C792F88F777Q34232286-C5F48B28-7528-410C-8AC9-852265D04B89Q34253787-2A5AE449-9E81-4404-860F-4C1D27870061Q34292754-0D047C22-4EF4-41B2-A984-DAD56E0662D9Q35576598-7B66440A-B31D-46B7-8016-21A8990710C8Q35691213-73339D0F-9D7F-4F08-80E1-E033B8EBE64BQ35799846-6E24F2A3-11A2-4CD0-A364-68855D069E82Q35833310-033EA4C4-6EF0-4B33-A22C-A9CCABC3B6E0Q35875805-8DBE4600-6CD9-41BC-A988-FB26DAE95693Q36209156-571DFDD9-BDE9-476C-B497-C6799B12F84CQ36344412-CF7C255D-4C3E-4F19-8532-CA9700876D2EQ36586105-79FD5EEE-2BCD-4B13-AF9D-C89439D1D17DQ37168973-451EA67B-0C65-4D50-A091-18A74A8D8386Q37561623-772AC75D-49CC-41F0-90E9-06E091D3CB75Q37803420-CD9F2151-77E7-4BE1-8042-11D7068D55F0Q37853071-0AFAE92B-8A59-43EA-8385-BCAC1EA4A1A7Q37975550-812D615F-BC3A-4679-A004-6620C1A00D7DQ37983613-9BF8D84C-BF53-4EFA-921C-0F7B8306B935Q38005778-602124A0-7D5C-489B-942F-F9EFC41C5DFAQ38065287-6826A340-BF96-41C5-BD6C-1B19FC455FA6Q38067497-9AE985CF-F6E5-4F54-B863-9E93B20BE7EDQ38187892-59C9C27D-2CC0-4728-A4FF-960505C5F09FQ38221823-A5954BCA-B8C2-4C03-99FB-8D4AA6C7E3C1Q38271152-A5AA9748-DA83-4704-AB3B-AEF1CBF9E031Q38370764-1A39653B-B2EC-430C-99DE-922D1B4A7675Q38651980-686FC96C-084D-47B0-8002-916789F3E516Q38732635-E96CFCDB-CC35-4536-8E37-2D3B9B5B471D
P2860
Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse
description
2009 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունիսին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2009
@ast
im Juni 2009 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: June 2009)
@en
vedecký článok (publikovaný 2009-06)
@sk
vědecký článek publikovaný v roce 2009
@cs
wetenschappelijk artikel (gepubliceerd in 2009-06)
@nl
наукова стаття, опублікована в червні 2009
@uk
مقالة علمية (نشرت في يونيو 2009)
@ar
name
Abuse liability and safety of ...... h a history of stimulant abuse
@ast
Abuse liability and safety of ...... h a history of stimulant abuse
@en
Abuse liability and safety of ...... h a history of stimulant abuse
@nl
type
label
Abuse liability and safety of ...... h a history of stimulant abuse
@ast
Abuse liability and safety of ...... h a history of stimulant abuse
@en
Abuse liability and safety of ...... h a history of stimulant abuse
@nl
prefLabel
Abuse liability and safety of ...... h a history of stimulant abuse
@ast
Abuse liability and safety of ...... h a history of stimulant abuse
@en
Abuse liability and safety of ...... h a history of stimulant abuse
@nl
P2860
P3181
P356
P1476
Abuse liability and safety of ...... h a history of stimulant abuse
@en
P2093
D R Jasinski
S Krishnan
P2860
P304
P3181
P356
10.1177/0269881109103113
P407
P577
2009-06-01T00:00:00Z